Evidence map›Paper›PMID 35186376›Full record

ArticleChina CDC weekly2022

Factors Associated with SARS-CoV-2 Repeat Positivity - Beijing, China, June-September 2020.

Siqi Li, Xiaoli Wang, Li Li, Yang Pan, Siyuan Yang, Dawei Tan, Ying Shen, Peng Yang, Naor Bar-Zeev, Yaling Hu and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in China CDC weekly, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Siqi LiBeijing Center for Disease Prevention and Control, Beijing, China.
Xiaoli WangBeijing Center for Disease Prevention and Control, Beijing, China.
Li LiEmergency department of Infectious diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Yang PanBeijing Center for Disease Prevention and Control, Beijing, China.
Siyuan YangLaboratory of Infectious Diseases Center of Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Dawei TanEmergency department of Infectious diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Ying ShenBeijing Center for Disease Prevention and Control, Beijing, China.
Peng YangBeijing Center for Disease Prevention and Control, Beijing, China.
Naor Bar-ZeevDepartment of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Yaling HuSinovac Biotech Co, Ltd, Beijing, China.
Jacky M JenningsDepartment of Pediatrics, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Simin LiYiducloud (Beijing) Technology Co., Ltd, Beijing, China.
Linghang WangEmergency department of Infectious diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Quanyi WangBeijing Center for Disease Prevention and Control, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRepeat positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) following COVID-19 initial viral clearance (re-positivity) poses a public health management challenge. The objective was to determine factors associated with neutralizing antibody (Nab) level and re-positivity among patients infected with a single strain SARS-CoV-2.

methodsDuring a single strain SARS-CoV-2 cluster in Beijing, China, longitudinal individual clinical, virological, and immunological data were collected from 368 infections from June 13 to September 22, 2020. Factors associated with Nab level and re-positivity were analyzed using generalized estimating equations.

resultsA total of 353 (96%) SARS-CoV-2 infections had demographic, clinical, and laboratory data available. Among the 353 infections, 55 (15.5%) were re-positive, and blood draws were taken from 346 individuals (98.0%) during hospitalization and/or during the follow-up period. Symptoms were milder for the second-time admission for the re-positives, although 36.4% of re-positives presented with radiographic appearance of pneumonia manifestation. Compared to non-re-positive patients, NAb titers were lower among re-positives; NAb was positively associated with clinical severity. Samples from the lower respiratory tract manifested higher viral load than that from the upper respiratory tract. Multivariable analysis showed re-positivity was positively associated with being female [odd ratio (OR)=1.7, 95% confidence interval (CI) 1.1-2.8] and being aged <18 years (OR=5.2, 95% CI 1.5-18.1); having initially asymptomatic infection (OR=13.7, 95% CI 1.6-116.3); and negatively associated with a higher NAb level (OR=0.9, 95% CI 0.5-1.7).

conclusionsNAb may be important for sustained viral clearance. Lower respiratory tract infection was associated with higher viral load among all infections when compared to upper respiratory tract infection. Continuous lower respiratory and intermittent upper respiratory viral shedding among COVID-19 infections may occur.

Indexed as

COVID-19Neutralizing antibodyRepeated positivityViral load

Identifiers

PMID35186376
PMCPMC8837463

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.